IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
IO Biotech, Inc. (IOBT)
Company Research
Source: GlobeNewswire
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company’s lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company’s executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. “Marjan’s extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercial readiness phase for IO102-IO103,” said Dr. Zocca. “We’re thrilled to welcome Marjan to the IO Biotech team as we continue to expand our pipeline with product candidates in multiple cancer indications where the T-Win platform may prove highly effective.” Dr. Shamsaei added, “It is an honor to
Show less
Read more
Impact Snapshot
Event Time:
IOBT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOBT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOBT alerts
High impacting IO Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
IOBT
News
- IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness [Yahoo! Finance]Yahoo! Finance
- IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103GlobeNewswire
- IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerGlobeNewswire
IOBT
Earnings
- 11/13/23 - Beat
IOBT
Analyst Actions
- 3/6/24 - HC Wainwright
IOBT
Sec Filings
- 4/26/24 - Form 8-K
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- IOBT's page on the SEC website